

ONCOLOGY AGENTS, ORAL PRIOR AUTHORIZATION FORM

Prior authorization guidelines for **Oncology Agents, Oral** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at <http://www.dhs.pa.gov/provider/pharmacyservices/drugsrequiringclinicalpriorauthorization/index.htm>.

PRIOR AUTHORIZATION REQUEST INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	Total # of pages: _____	
Name of office contact:		Prescriber name:	
Contact's phone number:		Specialty:	
Facility contact/phone:		State license #:	MA Provider ID#:
BENEFICIARY INFORMATION		Street address:	
Beneficiary name:		Suite #:	City/state/zip:
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Medication requested: (See question 3 below regarding agents in the Specialty Pharmacy Drug Program.) (NP) = non-preferred agent			
<input type="checkbox"/> Afinitor <input type="checkbox"/> Afinitor Disperz <input type="checkbox"/> Alecensa <input type="checkbox"/> Alunbrig <input type="checkbox"/> bicalutamide <input type="checkbox"/> Bosulif <input type="checkbox"/> Cabometyx <input type="checkbox"/> Calquence <input type="checkbox"/> capecitabine (NP) <input type="checkbox"/> Caprelsa <input type="checkbox"/> other: _____	<input type="checkbox"/> Casodex (NP) <input type="checkbox"/> Cometriq <input type="checkbox"/> Cotellic <input type="checkbox"/> Erivedge <input type="checkbox"/> Erleada <input type="checkbox"/> Farydak <input type="checkbox"/> Gilotrif <input type="checkbox"/> Gleevec <input type="checkbox"/> Ibrance <input type="checkbox"/> Iclusig	<input type="checkbox"/> Idhifa <input type="checkbox"/> imatinib (NP) <input type="checkbox"/> Imbruvica <input type="checkbox"/> Inlyta <input type="checkbox"/> Iressa <input type="checkbox"/> Jakafi <input type="checkbox"/> KISQALI <input type="checkbox"/> KISQALI Femara <input type="checkbox"/> Lenvima <input type="checkbox"/> Lonsurf	<input type="checkbox"/> Lynparza <input type="checkbox"/> Mekinist <input type="checkbox"/> Nerlynx <input type="checkbox"/> Nexavar <input type="checkbox"/> Ninlaro <input type="checkbox"/> Odomzo <input type="checkbox"/> Rubraca <input type="checkbox"/> Rydapt <input type="checkbox"/> Sprycel <input type="checkbox"/> Stivarga
<input type="checkbox"/> Sutent <input type="checkbox"/> Tafinlar <input type="checkbox"/> Tagrisso <input type="checkbox"/> Tarceva <input type="checkbox"/> Tasigna <input type="checkbox"/> Temodar <input type="checkbox"/> temozolomide <input type="checkbox"/> Tykerb <input type="checkbox"/> Venclexta <input type="checkbox"/> Verzenio	<input type="checkbox"/> Votrient <input type="checkbox"/> Xalkori <input type="checkbox"/> Xeloda <input type="checkbox"/> Xtandi <input type="checkbox"/> Zejula <input type="checkbox"/> Zelboraf <input type="checkbox"/> Zolanza <input type="checkbox"/> Zydelig <input type="checkbox"/> Zykadia <input type="checkbox"/> Zytiga	Strength & dosage form: _____ Directions: _____ Quantity: _____ Refills: _____	
1. What is the beneficiary's diagnosis?		<i>Submit documentation confirming diagnosis, such as chart notes, lab results, biopsy results, etc.</i>	
2. What is the corresponding diagnosis code?			
3. Is the medication being prescribed by, or in consultation with, a hematologist or oncologist?		<input type="checkbox"/> Yes <input type="checkbox"/> No	
4. Most oral oncology agents are included in the Department's Specialty Pharmacy Drug Program (SPDP). Which specialty pharmacy will be used? (Refer to the Department's SPDP website for more information: http://www.dhs.pa.gov/provider/pharmacyservices/thespecialtypharmacydrugprogram/index.htm .)		<input type="checkbox"/> Diplomat Specialty Pharmacy <input type="checkbox"/> Walgreen's Specialty Pharmacy	
5. For non-preferred requests only [drugs marked above with (NP)] , does the beneficiary have a history of trial and failure, contraindication, or intolerance to the preferred alternative agent (i.e., the preferred therapeutically equivalent (AB-rated) brand or generic product), or has the beneficiary taken the non-preferred medication in the past 90 days?		<input type="checkbox"/> Yes – <i>Submit all supporting documentation of drug regimen tried and treatment outcomes.</i> <input type="checkbox"/> No	
6. For renewal requests only , since the requested medication was started, has the beneficiary experienced a positive clinical response to therapy?		<input type="checkbox"/> Yes – <i>Submit documentation of beneficiary's response to therapy.</i> <input type="checkbox"/> No	

PLEASE FAX COMPLETED FORM WITH SUPPORTING CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature: _____	Date: _____
-----------------------------	-------------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.